
## Masaki Hashimoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3950471/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Japanese Current Status of Curative-Intent Surgery for Malignant Pleural Mesothelioma. Annals of Thoracic Surgery, 2022, 113, 1348-1353.	1.3	10
2	Circulating tumor cell methylation profiles reveal the classification and evolution of non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 224-237.	2.8	7
3	Control of air leakage during pleurectomy/decortication by the ventilation and anchoring method. General Thoracic and Cardiovascular Surgery, 2022, 70, 730-734.	0.9	3
4	Association between thoracic epidural block and major complications after pleurectomy/decortication for malignant pleural mesothelioma under general anesthesia. Regional Anesthesia and Pain Medicine, 2022, 47, 494-499.	2.3	2
5	Complications and Predictive Factors for Air Leak > 10 Days with Neoadjuvant Chemotherapy Followed by Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Annals of Surgical Oncology, 2021, 28, 3057-3065.	1.5	11
6	Clinicopathological features of radiological early malignant pleural mesothelioma with no apparent tumor or pleural thickening. International Journal of Clinical Oncology, 2021, 26, 95-103.	2.2	2
7	Outcomes of Conversion to Extrapleural Pneumonectomy From Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 873-881.	0.6	7
8	Usefulness of Quantitative Bone Single-Photon Emission Computed Tomography/Computed Tomography for Evaluating the Treatment Response of Bone Metastasis in a Lung Cancer Patient. Case Reports in Oncology, 2021, 14, 391-396.	0.7	2
9	Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT. Cancers, 2021, 13, 1098.	3.7	7
10	Quality of life and lung function after pleurectomy/decortication for malignant pleural mesothelioma. Interactive Cardiovascular and Thoracic Surgery, 2021, 33, 572-579.	1.1	5
11	Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis. Oncotarget, 2021, 12, 1187-1196.	1.8	4
12	One-Stage Robotic Resection for Thoracic Dumbbell Tumor Without Repositioning. Annals of Thoracic Surgery, 2021, 112, e83-e85.	1.3	2
13	Relationship Between Physical Function and Health Utility in Patients Undergoing Surgical Treatment for Malignant Pleural Mesothelioma. Integrative Cancer Therapies, 2021, 20, 153473542110435.	2.0	3
14	A Surgical Case of Pancreatic Metastasis from Lung Cancer. International Surgery, 2021, 105, 316-321.	0.1	0
15	Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 5793-5802.	1.1	9
16	Right Lower Lobectomy for an Aberrant Mediastinal Inferior Lobar Artery. Annals of Thoracic Surgery, 2020, 109, e415-e417.	1.3	6
17	Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma, Nuclear Medicine Communications, 2020, 41, 790-799.	1.1	5
18	Treatment of bronchial fistula after extraplural pneumonectomy using flexible bronchoscopy with the administration of OK432, fibroblast growth factor basic and fibrin glue sealant. General Thoracic and Cardiovascular Surgery, 2020, 68, 1562-1564.	0.9	1

Masaki Hashimoto

#	Article	IF	CITATIONS
19	Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma. Japanese Journal of Clinical Oncology, 2020, 50, 920-925.	1.3	10
20	Non-incisional pleurectomy/decortication. European Journal of Cardio-thoracic Surgery, 2020, 58, 186-187.	1.4	6
21	Clinical feature of diagnostic challenging cases for pleural biopsy in patient with malignant pleural mesothelioma. General Thoracic and Cardiovascular Surgery, 2020, 68, 820-827.	0.9	7
22	Clinical Outcomes With Recurrence After Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Annals of Thoracic Surgery, 2020, 109, 1537-1543.	1.3	23
23	Development of an effective method utilizing fibrin glue to repair pleural defects in an ex-vivo pig model. Journal of Cardiothoracic Surgery, 2020, 15, 110.	1.1	6
24	A Retrospective Single-Institutional Analysis of the Usefulness of Pleural Effusion-Cell Block for Diagnosing Malignant Pleural Mesothelioma. Japanese Journal of Lung Cancer, 2020, 60, 972-978.	0.1	0
25	Three tumor markers for improved efficacy in the management of patients with malignant pleural mesothelioma. Journal of Thoracic Disease, 2020, 12, 6712-6721.	1.4	0
26	Three tumor markers for improved efficacy in the management of patients with malignant pleural mesothelioma. Journal of Thoracic Disease, 2020, 12, 6712-6721.	1.4	4
27	Physical function and health-related quality of life in the convalescent phase in surgically treated patients with malignant pleural mesothelioma. Supportive Care in Cancer, 2019, 27, 4107-4113.	2.2	8
28	Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 404-413.	0.8	23
29	Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma. Seminars in Thoracic and Cardiovascular Surgery, 2019, 31, 301-309.	0.6	24
30	Correlation between peripheral CD8+PD-1+ T cells diversity, tumor mutation burden (TMB) and T cell clones with anti-PD-1 antibody treatment of lung cancer patients: TCR repertoire as a novel predictive biomarker Journal of Clinical Oncology, 2019, 37, e14041-e14041.	1.6	1
31	Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma – Comparison with contrast-enhanced CT. Oncotarget, 2019, 10, 6816-6828.	1.8	8
32	Survival impact of thoracic cavity reduction during neoadjuvant chemotherapy in patients undergoing surgery for malignant pleural mesothelioma Journal of Clinical Oncology, 2019, 37, e20067-e20067.	1.6	0
33	Outcome of neo-adjuvant chemotherapy in 225 surgical candidates with malignant pleural mesothelioma Journal of Clinical Oncology, 2019, 37, 8548-8548.	1.6	0
34	Poor Prognostic Factors in Patients with Malignant Pleural Mesothelioma Classified as Pathological Stage IB According to the Eighth Edition TNM Classification. Annals of Surgical Oncology, 2018, 25, 1572-1579.	1.5	1
35	Radiofrequency Ablation Effectively Treated Focal Recurrence of Mesothelioma. Annals of Thoracic Surgery, 2018, 105, e265-e267.	1.3	0
36	Methadone for management of persistent pain after extrapleural pneumonectomy. The Journal of the Japanese Association for Chest Surgery, 2018, 32, 88-93.	0.0	0

#	Article	IF	CITATIONS
37	Positive correlation between postoperative tumor recurrence and changes in circulating tumor cell counts in pulmonary venous blood (pvCTC) during surgical manipulation in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 298-306.	1.4	28
38	The clinical value of circulating tumour cells (CTCs) in patients undergoing pulmonary metastasectomy for metastatic colorectal cancer. Journal of Thoracic Disease, 2018, 10, 1569-1577.	1.4	11
39	CDK4/6 inhibitor and radiation therapy in malignant pleural mesothelioma Journal of Clinical Oncology, 2018, 36, e24326-e24326.	1.6	5
40	Circulating Tumor Cell Count Can Be a Useful Prognostic Factor in Lung Resection via Cardiopulmonary Bypass. Case Reports in Oncology, 2017, 10, 169-174.	0.7	1
41	Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy. International Journal of Clinical Oncology, 2017, 22, 857-864.	2.2	10
42	Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma. Supportive Care in Cancer, 2017, 25, 2569-2575.	2.2	14
43	Prognostic value of pretreatment volume-based quantitative 18 F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. European Journal of Radiology, 2017, 86, 176-183.	2.6	23
44	A case report of reverse latissimus dorsi muscle flap for subphrenic abscess and bronchial fistula. The Journal of the Japanese Association for Chest Surgery, 2017, 31, 800-804.	0.0	0
45	Lung metastases in an atypical type A thymoma variant. Journal of Thoracic Disease, 2017, 9, E805-E807.	1.4	3
46	Circulating tumor cell (CTC) as a significant prognostic factor in resected primary lung cancer Journal of Clinical Oncology, 2017, 35, e23044-e23044.	1.6	1
47	Slow-Growing Mediastinal Grey Zone Lymphoma Originating From a Formerly Resected Multilocular Thymic Cyst. Annals of Thoracic Surgery, 2016, 102, e561-e563.	1.3	2
48	A case of pulmonary metastasis from poorly differentiated thyroid carcinoma 43 years after thyroidectomy. The Journal of the Japanese Association for Chest Surgery, 2016, 30, 14-18.	0.0	0
49	Analysis of critical situations in thoracic surgery. The Journal of the Japanese Association for Chest Surgery, 2016, 30, 794-799.	0.0	Ο
50	A case of atypical type A thymoma variant. Surgical Case Reports, 2016, 2, 116.	0.6	4
51	The significance of RB expression in malignant pleural mesothelioma in multidisciplinary treatment including extrapleural pneumonectomy Journal of Clinical Oncology, 2016, 34, e20082-e20082.	1.6	Ο
52	MICS position is safe and effective in thoracoscopic surgery for anterior mediastinum tumor. The Journal of the Japanese Association for Chest Surgery, 2015, 29, 912-915.	0.0	0
53	Gene Mutation Analysis in Determining Late Recurrence of Adenocarcinoma of the Lung. Annals of Thoracic Surgery, 2015, 100, 711-713.	1.3	1
54	Circulating tumor cell (CTC) as a prognostic marker in primary lung cancer Journal of Clinical Oncology, 2015, 33, e22041-e22041.	1.6	1

Masaki Hashimoto

#	Article	IF	CITATIONS
55	ERCC1 in patients with Malignant Pleural Mesothelioma (MPM) treated by neoadjuvant chemotherapy followed by extrapleural pneumonectomy (EPP) Journal of Clinical Oncology, 2015, 33, e18542-e18542.	1.6	1
56	Determining association between activation of mTOR signal pathway and patient with malignant pleural mesothelioma who underwent a multimodality therapy including extrapleural pneumonectomy Journal of Clinical Oncology, 2015, 33, e18543-e18543.	1.6	1
57	Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. Interactive Cardiovascular and Thoracic Surgery, 2014, 18, 775-783.	1.1	95
58	A surgical case of primary pulmonary synovial sarcoma confirmed by the detection of an SYT-SSX1 fusion gene. International Cancer Conference Journal, 2014, 3, 128-131.	0.5	1
59	Blood tests in malignant pleural mesothelioma (MPM) Journal of Clinical Oncology, 2014, 32, 7582-7582.	1.6	1
60	Association of activation of mTOR and MAPK signal pathway with prolonged survival in patients with malignant pleural mesothelioma Journal of Clinical Oncology, 2014, 32, 7585-7585.	1.6	0
61	Combination efficacy of mTOR and MEK inhibitor in malignant pleural mesothelioma (MPM) Journal of Clinical Oncology, 2013, 31, e18557-e18557.	1.6	2
62	Practical approaches to diagnose and treat for TO malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy. International Journal of Clinical Oncology, 2012, 17, 33-39.	2.2	14
63	Novel malignant-mesothelioma-associated antigens (Gene-X and THBS-2) in the diagnosis of malignant pleural mesothelioma (MPM) Journal of Clinical Oncology, 2012, 30, 10585-10585.	1.6	0
64	Circulating tumor cell (CTC) as a significant clinical marker in epithelioid-type malignant pleural mesothelioma (MPM) Journal of Clinical Oncology, 2012, 30, 7080-7080.	1.6	0
65	Increase in Serum Lipid Peroxide Level and Development of Intimal Proliferation in Graft Coronary Artery after Heart Transplantation in Rats Journal of Clinical Biochemistry and Nutrition, 1993, 14, 113-119.	1.4	Ο